A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis (NCT07100119)
A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.
Who can join: Review the eligibility criteria below.
Location: UZ Leuven — Leuven
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- UZ Leuven — Leuven,
- Heritage Medical Research Clinic — Calgary,
- Walter Mackenzie Health Sciences Centre — Edmonton,
- London Health Sciences Centre — London,
- Montreal Neurological Institute and Hospital — Montreal,
- Sunnybrook Research Institute — Toronto,
- Universitätsklinikum Schleswig-Holstein — Lübeck,
- Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie — Rostock,
- Universitätsklinikum Ulm — Ulm,
- Universitair Medisch Centrum Utrecht — Utrecht,
- Hospital Universitario de Bellvitge — L'Hospitalet de Llobregat,
- Hospital Universitari i Politecnic La Fe — Valencia,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in ALS (Amyotrophic Lateral Sclerosis)
- T-regulatory Cells in ALS — Boston, Massachusetts
- Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro — Santa Barbara, California
- Tofersen in Non-SOD1 ALS — Atlanta, Georgia
- Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS — Santa Barbara, California
- Tongue-strengthening Exercises in People With ALS. — Davie, Florida
Explore by condition: All ALS (Amyotrophic Lateral Sclerosis) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.